Pierrel SpA
MIL:PRL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.735
1.745
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Pierrel SpA
Cost of Revenue
Pierrel SpA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pierrel SpA
MIL:PRL
|
Cost of Revenue
-€9.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-16%
|
|
|
Newron Pharmaceuticals SpA
SIX:NWRN
|
Cost of Revenue
-€462k
|
CAGR 3-Years
-45%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
|
Cost of Revenue
-€725.4m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
Friulchem SpA
MIL:FCM
|
Cost of Revenue
-€21.9m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Shedir Pharma Srl Unipersonale
MIL:SHE
|
Cost of Revenue
-€23.6m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Pierrel SpA
Glance View
Pierrel SpA engages in the development, manufacturing, and marketing of medical therapies for the pharmaceutical, bio-pharmaceutical, and life science industries. The company is headquartered in Capua, Caserta. The company went IPO on 2006-05-23. The firm specializes in the pharmaceutical research, development and the manufacture of medicines. The company operates through three segments. The Contract Manufacturing segment covers research and development of various types of drugs, such as Tube vials, bottles, ampoules, drops, sprays, tablets and gels. The company manufactures the drugs in the production facility in Capua, which consists of warehouses, chemical and microbiological laboratories, offices and utilities buildings. The Pharma segment is active in the development, registration and licensing of new drugs and medical devices. The Tech-driven Contract Research & Development Organization segment provides research of existing drugs for the treatment of rare diseases, among others.
See Also
What is Pierrel SpA's Cost of Revenue?
Cost of Revenue
-9.7m
EUR
Based on the financial report for Jun 30, 2023, Pierrel SpA's Cost of Revenue amounts to -9.7m EUR.
What is Pierrel SpA's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-16%
Over the last year, the Cost of Revenue growth was -21%. The average annual Cost of Revenue growth rates for Pierrel SpA have been -13% over the past three years , -8% over the past five years , and -16% over the past ten years .
You don't have any saved screeners yet
